Skip to main content

Table 1 Demographics and clinical characteristics of study participants at enrolment

From: Three year survival among patients with aids-related Kaposi sarcoma treated with chemotherapy and combination antiretroviral therapy at Moi teaching and referral hospital, Kenya

 

GEM (n = 36)

BV (n = 34)

Total (n = 70)

p-value

Males

16 (44.4%)

24 (70.6%)

40 (57.1%)

0.087

Age [years] (Median, IQR)

35.3 (30.0, 40.5)

36.9 (31.0, 44.1)

35.6 (30.6, 41.6)

0.565

Stage:

 0

1 (2.8%)

1 (2.9%)

2 (2.9%)

1.000

 1

35 (97.2%)

33 (97.1%)

68 (97.1%)

ECOG PS:

 0

19 (52.8%)

14 (41.2%)

33 (47.1%)

0.286

 1

17 (47.2%)

17 (50.0%)

34 (48.6%)

 2

0 (0.0%)

2 (5.9%)

2 (2.9%)

 3

0 (0.0%)

1 (2.9%)

1 (1.4%)

CD4-cells/μL (Median, IQR)

225.0 (108.5, 310.0)

222.0 (63.8, 431.0)

224.0 (107.0, 360.5)

0.914

BSA [m2] (Median, IQR)

1.57 (1.50, 1.70)

1.67 (1.58, 1.79)

1.60 (1.50, 1.74)

0.0872

Duration of HIV diagnosis [months] (Median, IQR)

14.5 (4.8, 66.8)

12.0 (6.3, 38.0)

12.0 (6.0, 53.5)

0.722

Duration of AIDS-KS confirmed diagnosis [weeks] (Median, IQR)

5.4 (3.9, 8.8)

4.3 (3.0, 7.9)

4.8 (3.7, 8.6)

0.300

  1. Key: BV Bleomycin plus Vincristine, GEM Gemcitabine, ECOG PS Eastern Cooperative Oncology Group Performance Status, 67/70 Patients had good performance status. BSA Body Surface Area. Duration of KS from histology diagnosis to starting chemotherapy. Stage 1; Advanced KS, 68/70 patients had stage 1 KS according to ACTG criteria